Does serum B lymphocyte chemoattractant protein13 (CXCL13) level correlate with parameters of disease activity and severity in rheumatoid arthritis? Clinical and musculoskeletal ultrasonographic assessment

Egyptian Rheumatology and Rehabilitation

Mona M. Elbehisy¹  Shereen H. Ahmed²  Gamal A. Hamad³  Sami A. Egilla³  Eman A. Baraka³  Maiada A. Khalil³ 

[1] Clinical Pathology Department, Benha Faculty of Medicine, Benha University;Medical Microbiology and Immunology, Benha Faculty of Medicine, Benha University;Rehabilitation and Physical medicine, Benha Faculty of Medicine, Benha University;

关键词: Rheumatoid arthritis;    CXCL13 chemokine;    Disease activity;    Disease severity;    Musculoskeletal ultrasound;   

DOI  :  10.1186/s43166-020-00041-2

来源: DOAJ

【 摘 要 】

Abstract Background Rheumatoid arthritis (RA) affects about 1–3% of the population making it one of the most popular autoimmune diseases. Chemokines through switching on their receptors exert a climacteric role in RA pathogenesis. The purpose of this cross-sectional study was to quantify the serum levels of serum B lymphocyte chemoattractant protein13 (CXCL13) chemokine in recent onset RA patients and to correlate its levels with clinical, laboratory, and musculoskeletal ultrasonographic parameters (MSUS) of disease activity and severity. Results The mean serum CXCL13 value showed a significant increase in the RA patients (388.86 ± 283.63 pg/ml) than in the controls (62.94 ± 31.62 pg/ml) (P < 0.001). Highly active RA patients had significantly the highest mean of CXCL13 (mean ± SD 819.13 ± 191.05) compared with the moderately active RA patients (mean ± SD 284.95 ± 137.93) (P < 0.001) and the RA patients with low disease activity (mean ± SD 129.5 ± 21.27) (P < 0.001) and its levels were positively related with clinical disease activity and musculoskeletal ultrasonographic severity parameters. Conclusion Serum CXCL13 is correlated with clinical disease activity and MSUS disease severity that encourages its use for monitoring the activity and severity of synovitis in recent onset RA patients. Future studies to detect the effect of disease activity control by medications on CXCL13 levels and the effect of the CXCL13 antagonist on controlling RA disease activity and severity are recommended.

【 授权许可】

Unknown